<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21116">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831998</url>
  </required_header>
  <id_info>
    <org_study_id>ZX-ZP-0073 / 865-105</org_study_id>
    <nct_id>NCT02831998</nct_id>
  </id_info>
  <brief_title>In-vivo Efficacy of Patient Preoperative Prep</brief_title>
  <official_title>Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zurex Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zurex Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to demonstrate the antimicrobial efficacy of the ZP
      Preoperative Prep on skin flora of the abdomen and inguinal regions of human subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial reduction</measure>
    <time_frame>10 minutes post product application</time_frame>
    <description>A 2-log per cm2 bacterial reduction on the abdomen region and a 3-log per cm2 bacterial reduction on the inguinal region is considered a success.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin Irritation</measure>
    <time_frame>30 seconds to 6 hours</time_frame>
    <description>Safety as assessed by Skin Irritation score (erythema, edema, rash, dryness) of 0-3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial reduction</measure>
    <time_frame>30 seconds post product application</time_frame>
    <description>A 2-log per cm2 bacterial reduction on the abdomen region and a 3-log per cm2 bacterial reduction on the inguinal region is considered a success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial reduction</measure>
    <time_frame>6 hours post product application</time_frame>
    <description>Skin flora does not return to baseline on the abdomen and inguinal region is consider a success.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Surgical Skin Preparation</condition>
  <arm_group>
    <arm_group_label>ZP (70% IPA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isopropyl alcohol (IPA) 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ChloraPrep</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZP Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ZP without IPA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZP</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>ZP (70% IPA)</arm_group_label>
    <other_name>Isopropyl alcohol 70%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ChloraPrep</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>ChloraPrep</arm_group_label>
    <other_name>CHG 2%/IPA 70%</other_name>
    <other_name>Chlorhexidine gluconate 2% / Isopropyl alcohol 70%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZP Vehicle</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>ZP Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of any race

          -  Subjects in good health

          -  Minimum skin flora baseline requirements on abdomen and groin

          -  Skin free of tattoos, dermatoses, abrasions, cuts, lesions, or other skin disorder
             near or on the applicable test area.

        Exclusion Criteria:

          -  Topical or systemic antimicrobial exposure within 14 days prior to screening and
             treatment days, including antibiotics.

          -  Subjects with a history of skin sensitivity, skin allergies, or skin cancer.

          -  Subjects who are pregnant, attempting pregnancy or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MicroBioTest Laboratories</name>
      <address>
        <city>Sterling</city>
        <state>Virginia</state>
        <zip>20164</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad H. Bashir</last_name>
      <phone>703-925-0100</phone>
      <email>muhammad.bashir@microbac.com</email>
    </contact>
    <investigator>
      <last_name>M. Hamid Bashir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 10, 2016</lastchanged_date>
  <firstreceived_date>July 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
